Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Double-crane Pharmaceutical To Set Up Subsidiary In Liaoning

This article was originally published in PharmAsia News

Executive Summary

Beijing Double-crane Pharmaceutical has announced plans to invest RMB 100 million ($14.6 million) to set up a wholly-owned subsidiary named Liaoning Double-crane in Liaoning province, with plans to establish a medical transfusion product line. Present transfusion packaging firms in China's northeast region are small-scale operations producing glass bottles. Plastic transfusion bags are increasingly replacing glass, showing a huge development potential and opportunity for Double-crane. Meanwhile, the company will loan RMB 62.36 million ($9.10 million) to subsidiary Beijing Wanhui Double-crane Pharmaceutical to set up a U.S. FDA-cGMP-compliant solid pharmaceutical formulation base. The move marks the corporation's first concrete step into the American and European market. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel